The importance of a favorable safety profile to the overall success of a pharmaceutical product is well known. While most of the analysis of safety data is routine and exploratory in nature, we will discuss some options to examine safety data in greater detail. Some of these options represent recent advancements in the statistical and graphical procedures to present and analyze safety data.
LazarouJPomeranzBHCoreyPNIncidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA. 1998;279(15):1200–1205.
3.
GilbertGS ed. Drug Safety Assessment in Clinical Trials. New York, NY: Marcel Dekker, Inc.; 1993.
4.
Chuang-SteinC.“Statistics for safety data.” Chapter 9 in Detection of New Adverse Drug Reactions. 4th ed.London, UK: Macmillan Publisher; 1998.
5.
CrossGraphs. User Guide and Graph Types. Cambridge, MA: Belmont Research, Inc.; 1998.
6.
AnelloCO'NeillRTDoes research synthesis have a place in drug regulatory policy? Synopsis of issues: Assessment of safety and postmarketing surveillance. Clin Research Reg Aff.1996;13(1):13–21.
7.
SakaiHHayashiKOrigasaHKusunokiT.An application of meta-analysis techniques in the evaluation of adverse experiences with antihypertensive agents. Pharmacoepid Drug Safety. 1999;8:169–177.
8.
DuMouchelW.Bayesian data mining in large frequency tables, with an application to the FDA Spontaneous Reporting System (with discussion). Am Statistician. 1999;53:177–202.
